Prescription Drug Product Submissions Flashcards

You may prefer our related Brainscape-certified flashcards:
0
Q

Public Health Service Act of 1944

A

a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Federal Food, Drug, and Cosmetic Act of 1938

A

a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drug Price Competition and Patent Term Restoration Act of 1984

A

Hatch-Waxman Act -

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prescription Drug Marketing Act of 1987

A

a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prescription Drug User Fee Act of 1992

A

PDUFA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Federal Advisory Committee Act of 1972

A

a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Food and Drug Administration Modernization Act of 1997

A

FDAMA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Food and Drug Administration Amendments Act of 2007

A

FDAAA - If FDA becomes aware of new safety information about a serious risk associated with a drug’s use, the agency can require a manufacturer to implement safety labeling changes, conduct postmarketig studies or clinical trials, or establish Risk Evaluation and Mitigation Strategies (REMS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Food and Drug Administration Safety and Innovation Act of 2012

A

FDASIA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

21 CFR 314

A

Applications for FDA approval to market a new drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

21 CFR 601

A

Licensing (biological products)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Target Product Profile

A

TPP - is a format for a summary of the drug development program described in term of labeling concepts. It is prepared by the sponsor and submission is voluntary. It links each specific labeling concept to a specific study or other source of data that is intended to support the labeling concept.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Drug Development Tools

A

DDT - animal models, biological marker and clinical outcomes assessments (COAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Breakthrough Therapy Designation

A

FDASIA made available to expedite the development of therapies that show substantial promise in early clinical trials. Drug needs to be for a serious and life-threatening disease, and preliminary clinical evidence shows the drug may offer substantial improvement over existing therapies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Priority Review

A

Given to drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists. FDA reviews more quickly than standard applications. Fast Track are also eligible for Priority Review but does not automatically convey a Priority Reivew. Applicant must request it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Accelerated Approval

A

21 CFR 314 Subpart H (drugs) Subpart E (Biologics) - Created in 1992. Allows approval of rugs based on surrogate end-points that are reasonably likely to predict clinical benefit under these conditions 1) The disease must be serious or life-threatening 2) The treatment must provide meaningful therapeutic benefit over existing treatments

16
Q

Fast Track Designation

A

Designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases and that have the potential to address unmet medical needs. Eligible for “rolling review” allowing earlier submission and initiation of review. Can only be granted upon submission of an IND. Will respond within 60 days of reciept

17
Q

Rolling Reivew

A

FDA may consider reviewing portions of a marketing application before the complete NDA or BLA is submitted. To qualify Fast Track must have bene granted and the pivotal study must be complete or near completion

18
Q

Risk Evaluation and Mitigation Strategy

A

REMS - Allows FDA to require applicant of certain prescription drugs to submit a proposed REMS if the agency determines one is necessary to ensure that a drugs benefits outweigh it risks. Once notified sponsor must provided it within 120 days. Once FDA approves the REMS it will serve as the basis for inspection and enforcement. The drug will be considered misbranded if the applicant fails to comply with the approved REMS

19
Q

505(b)(2)

A

NDA - contains info required in a 505(b)(1) but applicant can provide some of the information required for approval in the form of studies it did not conduct and for which it has not obtained a right of reference. Added by Hatch-Waxman act to allow companies to develop alternative therapies quickly.

20
Q

505(b)(1)

A

NDA Traditional - Is a complete NDA that contains all studies conducted y the applicant necessary to demonstrate safe and effective use. Has all info per 21 CFR 314.50

21
Q

505(j)

A

Abbreviated NDA - (ANDA) - applicant is not required to include preclinical and clinical data to demonstrate safety and effectiveness. It includes chemistry and Bioequivalence data to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality performance characteristics and intended use of reference listed drug (RLD)

22
Q

351(a)

A

Original BLA - complete BLA contains all studies conducted by the applicant necessary to demonstrate safety and efficacy as outlined in 21 CFR 601.2

23
Q

351(k)

A

Biosimilar BLA - an abbreviated BLA for products that have been shown to be biosimilar to or “interchangeable” with an FDA licensed biological product.